Related references
Note: Only part of the references are listed.Structure-Based Design of Inhibitors of Protein-Protein Interactions: Mimicking Peptide Binding Epitopes
Marta Pelay-Gimeno et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Design and synthesis of new bioisosteres of spirooxindoles (MI-63/219) as anti-breast cancer agents
Atul Kumar et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Recent Advances of p53-MDM2 Small Molecule Inhibitors (2011-Present)
Peng-Cheng Lv et al.
CURRENT MEDICINAL CHEMISTRY (2015)
Spirooxindoles: Promising scaffolds for anticancer agents
Bin Yu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2015)
Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction
Joana Soares et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2015)
Pharmacological reactivation of p53 as a strategy to treat cancer
J. Zawacka-Pankau et al.
JOURNAL OF INTERNAL MEDICINE (2015)
A tryptophanol-derived oxazolopiperidone lactam is cytotoxic against tumors via inhibition of p53 interaction with murine double minute proteins
Joana Soares et al.
PHARMACOLOGICAL RESEARCH (2015)
Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction (MDM2 Inhibitors) in Clinical Trials for Cancer Treatment
Yujun Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Synthesis and evaluation of spiroisoxazoline oxindoles as anticancer agents
Carlos J. A. Ribeiro et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
SAR405838: An Optimized Inhibitor of MDM2-p53 Interaction That Induces Complete and Durable Tumor Regression
Shaomeng Wang et al.
CANCER RESEARCH (2014)
Small-Molecule Inhibitors of Protein-Protein Interactions: Progressing toward the Reality
Michelle R. Arkin et al.
CHEMISTRY & BIOLOGY (2014)
Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Bo Hong et al.
CURRENT DRUG TARGETS (2014)
Synthesis of novel spiropyrazoline oxindoles and evaluation of cytotoxicity in cancer cell lines
Angelo Monteiro et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2014)
Discovery of AMG 232, a Potent, Selective, and Orally Bioavailable MDM2-p53 Inhibitor in Clinical Development
Daqing Sun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Drugging the p53 pathway: understanding the route to clinical efficacy
Khoo Kian Hoe et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
Recent advances in the synthesis of biologically active spirooxindoles
Maria M. M. Santos
TETRAHEDRON (2014)
Discovery of Potent and Orally Active p53-MDM2 Inhibitors RO5353 and RO2468 for Potential Clinical Development
Zhuming Zhang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2014)
Live-cell imaging of p53 interactions using a novel Venus-based bimolecular fluorescence complementation system
Joana Dias Amaral et al.
BIOCHEMICAL PHARMACOLOGY (2013)
Synthesis, in Vitro, and in Cell Studies of a New Series of [Indoline-3,2′-thiazolidine]-Based p53 Modulators
Alessia Bertamino et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of RG7388, a Potent and Selective p53-MDM2 Inhibitor in Clinical Development
Qingjie Ding et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
A Potent Small-Molecule Inhibitor of the MDM2-p53 Interaction (MI-888) Achieved Complete and Durable Tumor Regression in Mice
Yujun Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development
Binh Vu et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Mark Wade et al.
NATURE REVIEWS CANCER (2013)
Efficient synthesis of spiroisoxazoline oxindoles
Carlos J. A. Ribeiro et al.
TETRAHEDRON LETTERS (2012)
The Structure-Based Design of Mdm2/Mdmx-p53 Inhibitors Gets Serious
Grzegorz M. Popowicz et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2011)
The p53-MDM2/MDMX axis - A chemotype perspective
Kareem Khoury et al.
MEDCHEMCOMM (2011)
Synthesis of Benzisoxazoles by the [3+2] Cycloaddition of in situ Generated Nitrile Oxides and Arynes
Anton V. Dubrovskiy et al.
ORGANIC LETTERS (2010)
The first 30 years of p53: growing ever more complex
Arnold J. Levine et al.
NATURE REVIEWS CANCER (2009)
Synthesis of 3-substituted-2-oxoindole analogues and their evaluation as kinase inhibitors, anticancer and antiangiogenic agents
AH Abadi et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2006)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
One pot synthesis of some new spiro[3H-indol-3,5 '(4 ' H)-[1,2,4] oxadiazol]-2-ones and bis[spiro[3H-indol-3,5 '(4 ' H)-[1,2,4] oxadiazol]-2-ones]
J Azizian et al.
SYNTHETIC COMMUNICATIONS (2000)
Share Paper
